Additionally, we have demonstrated that MLN0128, a second generation dual TORC1/2 inhibitor, significantly attenuated MCC tumor growth in MCC cell line-derived (CDX) mouse models49, thus confirming that this pathway is a valid therapeutic target in MCC. The gene discussed is CRTC1; the disease is Merkel cell skin cancer.